Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) EBT Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed EBT Margin for 3 consecutive years, with 2204.0% as the latest value for Q2 2025.

  • Quarterly EBT Margin fell 186021700.0% to 2204.0% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 10083.01% through Dec 2025, up 3136389.0% year-over-year, with the annual reading at 10773.31% for FY2025, 85456031.0% down from the prior year.
  • EBT Margin for Q2 2025 was 2204.0% at Inhibrx Biosciences, down from 1610.67% in the prior quarter.
  • The five-year high for EBT Margin was 1858013.0% in Q2 2024, with the low at 156823.33% in Q2 2023.
  • Average EBT Margin over 3 years is 200569.03%, with a median of 3916.38% recorded in 2023.
  • The sharpest move saw EBT Margin surged 201483633bps in 2024, then plummeted -186021700bps in 2025.
  • Over 3 years, EBT Margin stood at 5628.76% in 2023, then crashed by -750bps to 47865.0% in 2024, then skyrocketed by 95bps to 2204.0% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 2204.0%, 1610.67%, and 47865.0% for Q2 2025, Q1 2025, and Q4 2024 respectively.